Randomized Trial of Tumor Lysate Particle Only Vaccine vs. Tumor Lysate Particle-loaded, Dendritic Cell Vaccine to Prevent Recurrence of Resected Stage III/IV Melanoma: 36-MonthAnalysis - Society for Immunotherapy of Cancer

The TLPO and TLPLDC (without G-CSF) vaccines improved 36-month DFS and OS in this randomized phase 2 trial. The efficacy of the TLPO and TLPLDC vaccines will be confirmed in a phase III trial in resected Stage III/IV melanoma pts.